Using retroviral vectors encoding enhanced green fluorescent protein (EGFP), we addressed to what extent expression of retroviral transgenes in hematopoietic cells depends on the multiplicity of infection (MOI) and on the halflife of the encoded protein. We show that an elevation of the MOI not only elevates the frequency of transduced cells, but also increases transgene expression levels and reduces interanimal variability in vivo (hematopoietic cells of C57BL/6J mice analyzed 13 weeks after transplantation). This suggests that the MOI has to be carefully controlled and should be adapted as desired for clinical studies when evaluating vector performance in preclinical models. The impact of protein stability is demonstrated by comparing vectors expressing EGFP or a destabilized variant with a C-terminal PEST-sequence, d2EGFP. The loss of expression
Introduction
Despite the wide application of retroviral vectors in experimental hematology and gene therapy, it is largely unknown to what extent the multiplicity of infection (MOI) and the half-life of the encoded protein influence the results achieved. For two reasons, these issues require special consideration: first, preclinical models of retroviral (including lentiviral) gene transfer are often performed with a MOI that may not be desirable for a clinical application, and second, stable reporter proteins such as enhanced green fluorescent protein (EGFP) have become increasingly popular for preclinical evaluation of vector performance. [1] [2] [3] [4] As far as the use of randomly integrating retroviral or lentiviral vectors for stable therapeutic gene transfer in hematopoietic cells is concerned, copy numbers should be limited to one or two transgenes per cell to minimize the risk of insertional mutagenesis of genomic with d2EGFP was more pronounced in terminally differentiated cells of the peripheral blood (Ͼ30 fold) than in progenitor cells (five-to 10-fold), indicating a stronger transcription of the retroviral promoter in progenitor cells and a predominant role of protein inheritance over de novo synthesis of transgenic protein in mature blood cells. This analysis reveals an important and differentiation-dependent contribution of protein half-life to the expression of retroviral vectors in hematopoietic cells, establishes d2EGFP as a more accurate reporter for determination of vector transcription, and also suggests that preclinical data obtained under conditions of high transduction rates or with vectors expressing stable reporter proteins require careful interpretation. Gene Therapy (2001) 8, 477-486.
sequences. [5] [6] [7] However, standard mouse studies often rely on coculture with high-titer ecotropic retroviral packaging cells to transduce repopulating hematopoietic cells. 4, [8] [9] [10] [11] Because under these experimental conditions neither retroviral particle numbers nor availability of the cellular receptor for the ecotropic envelope protein nor stem cell divisions appear to be limiting, highly efficient gene transfer to long-term repopulating cells can be achieved. Considering that retroviral vectors integrate into post-mitotic DNA, and thus in only one of the two postmitotic cells, gene transfer in Ͼ50% of cycling target cells requires a high multiplicity of infection (MOI) . 12 This inevitably results in a high frequency of cells harboring multiple, and sometimes more than 10, transgene integrations. 10, 12 The increased gene dosage is expected to elevate transgene expression, as recently demonstrated in tumor cells using lacZ-encoding vectors. 12 Another factor that may generate premature conclusions about the potency of a given gene transfer vector is the use of a sensitive reporter with a long protein halflife, such as EGFP. In a differentiating cell system, such as the hematopoietic system, accumulation of proteins in mature cells may either result from de novo synthesis in a given cell type, or from inheritance of RNA and protein from progenitor cells. EGFP indeed is a very stable protein, with a half-life that may exceed 24 h. 13 Thus, vectors that express EGFP, or other stable proteins such as certain cell surface markers, 11, 14 are not necessarily promising to express a given therapeutic protein to adequate levels in the cell type of interest.
The present study was undertaken to address both issues. Using retroviral vectors encoding EGFP we show how an elevated MOI produces a significant increase of reporter gene expression not only in transduced fibroblasts, but also in primary hematopoietic cells analyzed in vivo. This was achieved by controlled retroviral gene transfer with cell-free vector stocks of predefined titers. To avoid limitations related to receptor availability, retroviral particles were pseudotyped with the glycoprotein of the vesicular stomatitis virus (VSV-G). [15] [16] [17] Moreover, we demonstrate that the half-life of the encoded protein plays a substantial and differentiation-dependent role for transgene expression in hematopoietic cells. Interestingly, the greatest difference was observed in mature cells of the peripheral blood. This is shown by comparison of EGFP and a variant containing a C-terminal PEST sequence that mediates more rapid protein turnover. 13 
Results

Vector construction
Plasmid pUC19 was modified to create a simplified cloning strategy for construction of murine leukemia virusbased retroviral vectors. The resulting vector carries the enhancer/promoter of the myeloproliferative sarcoma virus (MPSV) to drive transcription in transfected cells and a small polylinker NotI-EcoRI-BamHI-HindIII for insertion of cDNAs in the position replacing the original retroviral gag gene. 18 In these constructs, the 3′LTR, which is the source of the U3 region after retroviral replication, is derived from spleen focus-forming virus (SFFVp) and can be exchanged for enhancer/promoter studies using unique restriction sites NheI and XhoI. The 5′ untranslated leader region, which determines efficacy of packaging in particles, splicing, and initiation of translation, 18 can be exchanged using restriction sites XbaI and NotI.
Three variants of EGFP were introduced into these vectors ( Figure 1 ). EGFP represents the standard cDNA with long protein half-life of Ͼ24 h, as used by most investigators. [1] [2] [3] [4] The d2EGFP variant with a C-terminal PEST sequence has a protein half-life of 1-2 h. 13 EGFPrev is a revertant of d2EGFP that arose spontaneously in a subcloning step in our laboratory; the C-terminal 7 amino acids of the PEST sequence of d2EGFP are deleted in EGFPrev, and a new stop codon is formed. Thus, RNA sequences of d2EGFP and EGFPrev are largely identical. A sequence alignment of the C-termini of the three variants is presented in Figure 1 . Sequences outside this region were identical, making differences in the transcriptional processing of the vectors unlikely.
Vector production and titration High titers (up to 5 × 10 6 particles/ml cell-free supernatant) of retroviral vectors with potentially mixed pseudotypes presenting the ampho-Env and/or the VSV-G protein were obtained by cotransfecting Phoenixampho packaging cells with retroviral vector plasmids and an expression plasmid for the VSV-G protein.
Because recovery of particles after ultracentrifugation of cellular supernatants was close to 100% (data not shown), most particles must have contained VSV-G and can therefore be addressed as VSV-G pseudotypes. At least four harvests of 7 ml each were obtained from one transfection in a 9-cm dish. Following standardized protocols, titers were highly reproducible in independent experiments. Titration of supernatants on SC-1 fibroblasts led to strong EGFP-expression (Figure 2a ) persisting for at least 2 weeks in transduced cells, which argued against pseudotransduction. As indicated in Figure 1 , unconcentrated supernatants with defined titers were used in the experiments described below.
Effect of MOI on reporter expression in fibroblasts Next, we addressed the influence of the MOI on reporter expression from retroviral vectors encoding EGFP. As a model system for cells that are largely unlimited in their susceptibility to retroviral transduction, we chose exponentially growing SC-1 fibroblasts. Cells were transduced with a MOI ranging from 0.03 to 15. The mean fluorescence of uncloned, and unselected, EGFP-expressing cells was determined 4 days after transduction. Strikingly, the mean fluorescence showed a highly significant increase when more than 40% of cells were EGFP + , as obtained with a MOI Ͼ1 (Figure 2a-d) . The increase in expression was almost linear when the MOI exceeded 3, very similar to the data obtained by others using lacZ vectors. 12 Thus, a high MOI in the range of 10 produced at least a log difference in the mean fluorescence. In contrast, the expression levels were almost constant when the MOI was adjusted between 0.03 and 0.5, resulting in 3-20% of cells being EGFP + . Roughly 50% of cells were transduced using a MOI of 1, and with a further increase of the MOI, the number of EGFP-expressing cells reached a plateau at 80%. This indicated that the remaining cells were refractory to retroviral transduction, possibly due to cell cycle quiescence.
Unselected cells were cloned and expanded for Southern blot analysis, which confirmed increased transgene copy numbers in cells transduced with high MOI (at least five copies per transduced cell at MOI of 10, data not shown). Very similar results were obtained with a large number of EGFP vectors, differing in defined mutations in the enhancer, the untranslated leader region or other cis-elements active in transcriptional or post-transcriptional gene regulation. When transducing cells with predefined, equivalent titers, differences in vector performance could also be reproduced when the MOI exceeded 0.5 (data not shown).
Effect of MOI on reporter expression in transplanted hematopoietic cells
To compare the in vivo performance of different retroviral vectors, conditions had to be defined that result in the transduction of murine hematopoietic cells with a controlled MOI. This was accomplished using cell-free VSV pseudotypes at a predefined MOI as described in Materials and methods. Here, we demonstrate the utility of this protocol by analyzing the impact of the MOI and protein half-life on the performance of retroviral EGFP vectors in hematopoietic cells in vivo.
As primary hematopoietic cells growing in suspension may differ from adherent SC-1 fibroblasts with respect to physical properties, cell cycle status and receptor availability, we performed an experiment to assess the role of the MOI on vector performance in transplanted murine hematopoietic cells in vivo. Ly5.1 + donor cells were transduced with cell-free VSV pseudotypes of SF␣11EGFPrev at an MOI of either 0.8 (low MOI) or 4.8 (high MOI), each transduction being repeated once within 24 h. The day after the second transduction, EGFP + bone marrow cells were present at a frequency of 1.1% (low MOI) and 16.6% (high MOI), clearly underestimating the marking efficiency in long-term repopulating cells. A multilineage Gene Therapy analysis of EGFP expression in blood and bone marrow cells was obtained 13 weeks after transplantation into irradiated Ly5.2 + recipients. As shown in Table 1 and Figure 3a , the group of mice having received cells transduced with the higher MOI showed a significantly increased frequency of EGFP+ cells in all developmental lineages and stages of the PB and BM analyzed (eg sixfold increase in Ly5.1 + leukocytes and Sca1 + progenitor cells). CD11b
+ myeloid cells expressing EGFP also showed a three-fold brighter fluorescence when compared with those from the low MOI group (P = 0.025). In all other hematopoietic lineages and stages analyzed, EGFP expression was also increased, but to a lesser extent (1.3 times to 1.7 times, with a P value of 0.03 in T cells, 0.065 in Ter119 + , and P Ͼ 0.1 in all other subpopulations, according to t test) (Figure 3b ). Moreover, the interanimal variability in EGFP marking and expression levels was consistently reduced when using the high MOI for transduction of repopulating cells (Table 1 PCR analysis detecting the retroviral transgene in cells from single colony-forming units (CFUs) plated from bone marrow harvested at week 13 after transplantation ( Table 1 for details. progenitors (R 2 = 0.84). Comparing the cytometric data with the PCR results, the probability of EGFP expression in Ly5.1 + cells, which were exclusively donor-derived, was in the range of 6.9% to 52.7% in the low MOI group, and 30.3% to 64.2% in the high MOI group (see Discussion).
Figure 3 Impact of the MOI on transgene expression in vivo (13 weeks after transplantation). Open columns represent high MOI, black columns represent low MOI. (a) Overview of mean frequency and standard deviation of EGFP-expressing cells in various hematopoietic stages and lineages. Peripheral blood cells were classified using CD4 and CD8 identification of T cells, B220 for B cells, and CD11b for myeloid cells; erythrocytes (Ery) and platelets (PLT) were identified by scatter characteristics. Bone marrow progenitor cells were stained with Sca1, and erythroid precursors with TER119. (b) Overview of mean EGFP fluorescence intensities (MFI) and standard deviations. The relative diffrence (RD) in the frequency of EGFP + cells (a) and EGFP fluorescence intensity depending on the elevation of the MOI (b) is indicated in numbers above each pair of columns. Note that the relative size of the standard deviation in (a) and (b) is generally reduced in the high MOI group. See
Taken together, these results demonstrate that the elevated MOI not only increased the frequency of gene marking and of cells expressing the transgene, but also produced a reduced interanimal variability, a significant elevation of transgene expression in T lymphocytes and CD11b + leukocytes in vivo, and a trend for higher expression in all other types of hematopoietic cells analyzed here.
Gene Therapy
Effect of protein half-life on expression of EGFP in vitro
Having demonstrated the contribution of the MOI for retroviral expression in hematopoietic cells, we also addressed the impact of protein stability. Retroviral vectors were generated that encode EGFP, EGFPrev, or d2EGFP, a variant with a greatly reduced half-life, under control of identical cis-elements. Using equivalent MOIs of these vectors, we transduced SC-1 fibroblasts, and a panel of cells representing different lineages of human or murine hematopoiesis (K562 chronic myeloid leukemia cells, WEHI-3B murine myeloid precursor cells, and F4-12-B2 murine erythroleukemia cells). Interestingly, the fluorescence intensity mediated by vectors expressing d2EGFP was more than one order of magnitude reduced compared with conventional EGFP or EGFPrev, with the strongest difference observed in WEHI-3B cells ( Figure  4a) .
To examine whether similar effects could be observed in primary human hematopoietic cells derived from umbilical cord blood, these were transduced using the same vector supernatants in a single hit protocol with predefined and equivalent titers. Upon flow cytometry performed 5 days after transduction, both CD34
+ progenitors and more mature CD34
− cells showed more than a log reduction of EGFP fluorescence when expressing destablized d2EGFP (Figure 4b ). It is noteworthy that the fluorescence levels mediated by d2EGFP were still sufficient for analysis by flow cytometry. Interestingly, the modification of the C-terminus distinguishing EGFPrev and EGFP also produced a significant (up to two-fold) attenuation in fluorescence ( Figure  4a ). We did not investigate whether this was an effect of protein half-life or fluorescence intensity. We also observed that a single point mutation that was randomly obtained after PCR of the EGFP cDNA (codon 255, Phe to Lys) produced a significant decrease of fluorescence levels (data not shown). Two conclusions can be drawn from these results: (1) the long protein half-life has a considerable contribution to the high sensitivity of the EGFP reporter; and (2) subtle alterations of the cDNA may produce significant changes in expression. Therefore, comparing different vectors containing EGFP is only possible when identical cDNAs are present.
The contribution of protein half-life to transgene expression in vivo is differentiation-dependent To assess the contribution of reporter protein half-life to transgene expression in vivo, repopulating murine BM cells were transduced with vectors SF␣11d2EGFP or SF␣11EGFPrev. The MOI (2 × 2) was adjusted based on previous titration of vector supernatants in SC-1 cells, to avoid a bias introduced by differences in transgene copy numbers. PCR analysis of single GM-CFU, derived from BM cells 11 weeks after transplantion, revealed a comparable marking efficiency (54% = 18/35 CFU for EGFPrev, and 43% = 15/35 CFU for d2EGFP). PB and BM cells of various hematopoietic lineages were analyzed by flow cytometry 9 and 11 weeks, respectively, after transplantation.
A strong reduction of fluorescence was found in all cell types transduced with vectors encoding short-lived d2EGFP (Figure 5a ). This result was in line with our findings made in cell lines and primary human cells analyzed in vitro ( Figure 4 ) and could hardly be explained by the slightly superior gene marking efficiency in favor of the construct expressing long-lived EGFPrev. Most striking was the effect of the protein half-life for vector expression in mature blood cells (Figure 5a, b) . While long-lived EGFPrev was readily detectable in mature, enucleated erythrocytes of the PB, d2EGFP was barely detectable. In contrast, d2EGFP-mediated fluorescence was clearly visible, although at low levels, in terminally differentiated nucleated cells of the PB. These results indicated de novo vector transcription in mature myeloid cells (CD11b + cells, expression gradually decreased with cellular differentiation (Figure 5a ). With long-lived EGFP, the reduction of cellular fluorescence could be explained, at least in part, simply on the basis of diminished protein content due to reduced cellular size; however, TER119 + BM cells expressing d2EGFP showed a disproportional reduction of fluorescence with reduction of cell size, indicating a differentiation-dependent decrease of de novo expression of the vector. Taken together, the loss of expression with d2EGFP was more pronounced in mature PB cells than
Figure 5 Impact of protein half-life on expression of EGFP in vivo. (a) Mean fluoresence intensity (MFI) values were monitored in murine peripheral blood (PB) and bone marrow (BM) cells 9 and 11 weeks, respectively, after transplantation with retrovirally transduced cells. Open columns show mean expression of EGFPrev, filled columns expression of d2EGFP. The relative difference (RD) of the MFI obtained with EGFPrev compared with d2EGFP is indicated in numbers above each pair of columns. Expression of d2EGFP in erythrocytes (Ery) of the PB was not detected; erythrocytes of the PB were analyzed with specific instrument setting and therefore, a direct comparison of the expression levels in these cells with the other cell types shown is not possible. CD4/CD8 was used for identification of T cells, B220 for B cells; CD11b for myeloid cells; CD34 for progenitor cells; TER119 for erythroid precursors, with large (L), medium (M) and small (S) subpopulations identified according to scatter characteristics. Mean values and standard deviations of six mice per group. (b) Dot plots illustrating the substantial role of protein stability for detection of EGFP in B cells and erythrocytes.
in BM progenitors (Figure 5a ) or cells assayed in vitro (Figure 4) , indicating a substantial contribution of 'maternal' protein and a reduced de novo synthesis in terminally differentiated cells. In contrast, the use of vectors expressing long-lived EGFP may have suggested a misleading conclusion of higher expression of the vector in terminally differentiated cells compared to progenitor cells (Figure 5a ).
Discussion
This study demonstrates that both MOI and half-life of the transgenic protein have a substantial impact on the results achieved with retroviral vectors in hematopoietic cells. These observations have interesting implications for gene therapy.
Therapeutic gene transfer in hematopoietic cells requires adequate expression levels from limited insertions of transgenes; examples are bone marrow chemoprotection by transfer of genes mediating cancer drug resistance, [19] [20] [21] antiviral intracellular immunization strategies, 22 or correction of lysosomal storage disorders. 5, 6 Recent clinical studies, 19, 23 trials with nonhuman primates, 24 and xenografts of human hematopoietic cells derived from either umbilical cord blood or mobilized peripheral blood, 3, [25] [26] [27] [28] indicate that therapeutic gene transfer may be feasible, provided that vectors are used that express at sufficient levels even when present at low copy numbers. To establish a murine model for gene therapy with a controlled, clinically relevant gene transfer frequency in repopulating hematopoietic cells, we used cell-free VSV-pseudotyped retroviral supernatants of predefined titers rather than coculture on packaging cells. Fibronectin-coated dishes may allow a similar efficiency when using amphotropic particles. 29 Alternatively, cell-free ecotropic or 10A1 Env-pseudotyped particles may also be a good choice. 17, 30 Cytokine cocktails which preserve the repopulation capacity of stem cells may lead to further improvements of mouse models. 31 Here, we showed that a six-fold elevation of the MOI (from 0.8 to 4.8) resulted in a corresponding increase (sixfold to 11-fold, depending on the subpopulation) in the frequency of hematopoietic cells expressing the reporter gene, EGFP. The fact that the gene marking efficiency, as documented by the PCR of CFUs plated 13 weeks after transplantation, was three-fold increased, indicates that some CFUs of the high MOI group may have contained more than one vector integration. This likely explains why vector expression was also generally elevated. The effect of the MOI on vector expression was most pronounced in CD11b + myeloid cells, suggesting that these may have originated, at least in part, from a long-lived, lineage-restricted progenitor that is most susceptible to retroviral gene transfer under the specific conditions used here (cytokine cocktail, VSV envelope protein). Evidence for such a lineage-restricted transplantable progenitor exists from studies in mice and xenotransplantation of human cells in NOD/SCID mice. 28 We expect that a further increase of the MOI would generate an even more striking increase of vector expression in hematopoietic cells, as demonstrated in the fibroblast model (Figure 2) . Moreover, our study indicates that an elevation of the MOI also reduces interindividual variability. This may be explained by an increased number of transduced repopulating cells contributing to polyclonal hematopoiesis, thus normalizing for integration site-dependent clonal variability. In addition, the presence of two or more copies of the transgene in single cells may reduce the likelihood for extinction of transgene expression.
Taken together, these observations suggest that preclinical gene therapy studies may better be performed with a realistic MOI that resembles a potential application in patients, where single or dual insertions are desirable to limit the risk of insertional mutagenesis.
Gene Therapy
Then, over-estimation of vector performance and premature clinical testing may be prevented, and the therapeutic window of vector expression may be more exactly determined. Similar considerations apply to the use of lentiviral vectors, which are often used at a very high MOI in preclinical models. 32, 33 In the present study, transduction of murine hematopoietic cells with controlled MOI was helpful to demonstrate the substantial impact of the stability of the transgenic protein on vector performance, an issue that has not been addressed previously. A long half-life of a therapeutic protein expressed from a retroviral vector in hematopoietic cells may be of particular relevance for the correction of a large number of genetic disorders affecting long-lived mature blood cells, such as macrophages, T cells, or erythrocytes. 5, 6, 23 In contrast, a short protein halflife would be desirable when the transgene has a regulatory function and is expressed from an inducible vector, as may be required to promote expansion of transgenic hematopoietic cells in vivo. 34 Both in cell lines in vitro and in murine hematopoietic cells in vivo, expression of an EGFP variant with reduced stability (d2EGFP) was up to 50-fold reduced compared with a long-lived EGFP that currently represents the marker of choice for a large number of preclinical investigations. Thus, the stability of the encoded protein is at least as relevant for the expression of a retroviral transgene as the choice of the enhancer/promoter, 35 or cis-elements influencing RNA processing. 18, 36 Interestingly, the reduced protein half-life of d2EGFP resulted in a very weak fluorescence in mature myeloid cells or lymphocytes and a loss of expression in mature erythroid cells. In contrast, expression in erythroid precursor cells was still detectable, but decreased with differentiation. Generally, the reduction of transgene expression caused by the shortened protein half-life was even more pronounced in terminally differentiated blood cells than in hematopoietic progenitors, indicating that transcription of the vector was more active in progenitor cells. This may have been overseen when relying on the use of a stable reporter such as EGFP.
This observation suggests that protein accumulation and inheritance of protein from ancestor cells is an important and previously unrecognized factor contributing to retroviral vector-mediated transgene expression in terminally differentiated cells. For example, the bright fluorescence of long-lived EGFP in mature lymphoid cells of the peripheral blood may at least in part reflect inheritance of protein from earlier stages of lymphoid development rather than active transcription of the retroviral vector, as it is known that retroviral transgenes may be subject to a reversible down-regulation in resting T cells. 37 If the vector encoded a less stable therapeutic sequence, eg ribozymes, RNA decoys or antisense RNA designed to counteract certain aspects of the life cycle of the human immunodeficiency virus in mature T cells or macrophages, 22 the therapeutic efficiency may therefore decrease more strongly than anticipated from the expression of EGFP. Similar considerations may apply to other therapeutic strategies, eg expression of antigens in dendritic cells (Lindemann et al, manuscript in preparation). The present work establishes d2EGFP as an interesting tool for such investigations. The major drawback in the use of d2EGFP is its clearly reduced sensitivity. It remains to be seen whether other variants of short-lived fluorescent proteins will be superior in that respect.
We conclude that expression of long-lived EGFP or other stable reporter proteins only indicates that the transgene must have been active at some stage in the developmental history of a given cell and does not necessarily reflect ongoing transcription. In contrast, shortlived proteins such as d2EGFP might give a more accurate report of active transgene expression. An interesting implication of this work is that prolonging protein halflife may represent a highly effective means of improving expression of therapeutic transgenes, especially in terminally differentiated cells.
Material and methods
Construction of retroviral vectors
To construct the retroviral vectors described here, the polylinker region of pUC19 was replaced with an oligonucleotide to introduce a new polylinker ScaI-XbaIHindIII-XhoI. The resulting plasmid, named pSHX, was opened using restriction enzymes XbaI and HindIII, for insertion of the NheI-KpnI fragment of the long terminal repeat (LTR) of MPSV along with the KpnI-HindIII fragment containing the 5′untranslated region of pSF11. 18 Restriction sites HindIII and XhoI were used to insert a fragment containing the polypurine tract and the 3′LTR, using an amplicon generated by proof-reading PCR (Pfupolymerase; Stratagene, Heidelberg, Germany) with primers U3RU5+HindIII (5′TCCAAGCTTCCTAACACGA GCCATAGATAG 3′ and LTRXhoTail (5′CTCGAGA ATGAAAGACCCCCGAGGTGGGCAGTCAATC 3′). The 3′LTR of the plasmid was derived from an attenuated variant of the polycythemic strain of SFFVp, which lacks the imperfect direct repeat present SFFVp cl5.7. 35, 38 The resulting basic vector was named pSF␣11(SHX). The cDNAs for d2EGFP and EGFP were excised from pd2-EGFP-N1 (Clontech, Heidelberg, Germany) and pEGFP-N1 (Clontech), respectively, subcloned into pKS + and then obtained as NotI fragments for insertion into the polylinker region of pSF␣11(SHX). Thus, monocistronic retroviral vector plasmids pSF␣11d2 and pSF␣11EGFP were generated. We also obtained a revertant of pSF␣11d2 that had a partial deletion at the C-terminus of d2EGFP, resulting in a frame shift at the end of the PEST sequence. This vector was named pSF␣11EGFPrev. Sequencing confirmed that pSF␣11EGFPrev was identical with pSF␣11d2 outside the C-terminus.
Cell lines
Mouse SC-1 fibroblasts (ATCC No. CRL-1404) and human 293 cell-based Phoenix ampho packaging cells were cultured in DMEM media, murine WEHI-3B monocytic leukemia cells (ATCC No. TIB68) in IMDM, murine F4-12-B2 erythroleukemia cells in MEM, and human chronic myeloid leukemia cells K562 (ATCC No. CCL-243) in RPMI. 35, 38, 39 Media (Gibco BRL, Eggenstein, Germany) were supplemented with 10% fetal calf serum (Sigma, Deisenhofen, Germany), 2 mm glutamate, 100 U/ml penicillin, 100 g/ml streptomycin (all Gibco BRL).
Retroviral vector production and titration
Using the calcium phosphate transfection Kit (PeqLab, Gö ttingen, Germany), 6 g of retroviral vector plasmids were cotransfected with 3 g of pVSV-G, 16 an expression vector for VSV-G (New Jersey strain), in Phoenix-ampho packaging cells that had been plated at a density of 7 × 10 6 cells in 9-cm dishes the day before transfection. Supernatants were harvested daily 1 to 4 days after transfection, filtered (0.4 m), and stored in aliquots at −70°C.
Thawed aliquots of cryopreserved supernatants were serially diluted in culture medium as indicated in Results, and used for transduction of SC-1 fibroblasts that had been harvested by trypsinization from exponentially growing cultures. Cells were suspended at a density of 1 × 10 5 /ml in media containing retroviral supernatants and protamine sulfate (Sigma) (4 g/ml). Then, cells were plated in single wells of six-well tissue culture plates and centrifuged for 1 h at 2000 r.p.m. (ෂ800 g) in a cell culture centrifuge (Beckman, Fullerton, CA, USA). Retrovirus-containing media were exchanged with fresh, retrovirus-free media the following day. Cells were grown for another 48 h before determining the frequency of EGFP + cells by flow cytometry.
Retroviral gene transfer in murine bone marrow cells using cell-free supernatants C57BL/6J-Ly5.1-Pep3b mice (Ly5.1 + ) were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). These and C57BL/6J mice with common leukocyte antigen Ly5.2 (Ly5.2 + ) were bred in the pathogen-free animal facility of the Heinrich-Pette-Institute. Experiments were performed with mice 12-16 weeks of age, according to animal experimental ethics guidelines. Bone marrow cells were harvested from tibiae and femures of male donor mice 4 days after intraperitoneal administration of 5-fluorouracil (Sigma) (150 mg/kg). After lysis of erythroid cells in a hypotonic buffer (0.34 m NH 4 Cl, 0.01 m KHCO 3 , 0.12 mm EDTA), mononuclear cells were prestimulated in IMDM media supplemented with 20% fetal calf serum, 0.1% bovine serum albumine, 2 mm glutamate, 100 U/ml penicillin, 100 g/ml streptomycin, and a growth factor cocktail comprising murine IL-3 (10 ng/ml), human IL-6 (200 U/ml), and murine SCF (50 ng/ml) (recombinant growth factors from Strathmann Biotech (Hannover, Germany). Mononuclear cells were not further enriched for a progenitor cell phenotype. Following 2 days of stimulation, cells were plated at a density of 2 × 10 6 /ml in fresh stimulation media with double growth factor concentration, and an identical volume of thawed, cellfree supernatants containing retroviral particles were added. The MOI, as indicated in Results, was kept in the range of 0.8-4.8, as calculated from previous titration of supernatant aliquots on SC-1 fibroblasts. Protamine sulfate (4 g/ml) was supplemented, and cells were centrifuged for 1 h at 2000 r.p.m. (ෂ600x g). The transduction was repeated after 24 h. The following day, ie around 96 h after harvest from donor mice, cells were transplanted by tail vein injection in lethally irradiated (9. Single colony PCR from murine colony-forming cells In the experiment addressing the role of the MOI, BM cells were isolated from mice killed 13 weeks after transplantion and plated to generate myeloid and erythroid CFUs in semi-solid media, according to the manufacturer's instructions (StemCell Technologies, Vancouver, Canada). Single colonies were isolated by pipetting and lysed in 100 l of a buffer containing 50 mm KCl, 10 mm Tris-HCl ph 7.5, 2.5 mm MgCl 2 , 0.45% NP-40, 0.45% Tween-20, and 400 g/ml proteinase K. Twenty-five l of lysed cells were added to 25 l of a PCR reaction mixture as recommended by the manufacturer (Taq Polymerase Kit; Qiagen, Hilden, Germany) to start a nested PCR for amplification of vector sequences. For the first round, primers U3 + (5′ GCCATTTTGCAAGGCA TGGAAA 3′) and N-term (5′ TGCGACTTGAACAC CGGC 3′) were used, and cycling conditions were (95°C 1 min, 62°C 1 min, 72°C 2 min) × 35. For the second round, 1 l of the PCR product was transferred to a new tube containing 25 l of PCR reaction mix with primers SF␣for (5′ CTGTATCTGGCGGTCCCGCGG 3′) and egfptermrev (5′ CGGCAGGTCGAGCTGGTCCTAC 3′), and cycling conditions were (95°C 1 min, 62°C 1.5 min, 72°C 2 min) × 35. The resulting product (392 bp) was visualized by agarose gel electorophoresis. Negative colonies were tested for the presence of amplifiable DNA in a PCR detecting genomic ␤-actin sequences. 27 For the experiment addressing the role of the protein half-life, BM cells were isolated from mice killed 11 weeks after transplantion and plated to generate granulocyte-macrophage colony-forming cells in semi-solid media containing mIL-3 and mGM-CSF. Here, negative colonies were tested for the presence of amplifiable DNA in a PCR using primers U3 + (see above) and U3 − (5′ GCGCGCTTGTCTTC 3′), which detect endogenous retroviral sequences of the mouse genome.
Retroviral gene transfer in human CD34
+ cells: a single hit protocol Using the MACS CD34 Multisort Cell Isolation kit (Miltenyi, Bergisch-Gladbach, Germany), human CD34 + cells were isolated from leukapheresis aliquots donated according to ethical guidelines. Transduction conditions were as described with the following modifications. 27 Serum-free media (X-vivo-10; BioWhittaker, Brussels, Belgium) was used and supplemented with human IL-3, TPO, IL-6 (each 20 ng/ml), SCF (50 ng/ml), and Flt-3 ligand (100 ng/ml) (PeproTech, Rocky Hill, NJ, USA). After 24 h of precultivation at 1.2 × 10 6 cells/ml, cells were plated at densities of 0.9 × 10 6 /ml on dishes preloaded with retroviral supernatants so that a maximal MOI of 5 was reached in a single hit transduction. Cells were centrifuged for 1.5 h at 800 g and 32°C. The day after transduction, cells were washed and kept in the conditions used for prestimulation.
Flow cytometry and statistics EGFP expression was analyzed on a FACScalibur cytometer (Becton Dickinson, Heidelberg, Germany) equipped with a 488 nm argon laser and 530/30 nm (FL1, EGFP) and 575/38 nm (phycoerythrin, PE) bandpass filters. SC-1 fibroblasts and mature erythroid cells of the murine PB were gated according to scatter criteria. Erythroid cells of the murine BM were identified using PE-conjugated monoclonal antibody TER119
Gene Therapy (PharMingen, Hamburg, Germany) and further subclassified by size according to forward scatter criteria. 40 Peripheral blood myeloid cells, B cells and T cells were labeled with PE-conjugated lineage-specific monoclonal antibodies (PharMingen) CD11b, B220, and a cocktail of CD4/CD8, respectively. For detection of human CD34
+ and CD13 + subpopulations, cells were analyzed using PE-conjugated monoclonal antibodies (Becton Dickinson). Gate criteria were adjusted according to isotype controls. Mean fluorescence of EGFP expression was determined using CellQuest software (Becton Dickinson). Standard deviations (s.d.) were calculated using Microsoft Excel software.
